{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:25:09Z","timestamp":1767173109042,"version":"build-2238731810"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":2005,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Academic Emergency Medicine"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    Celecoxib is a selective cyclooxygenase\u20102 (COX\u20102) inhibitor used to treat pain. The objective of this study was to compare the efficacies of celecoxib and ibuprofen for the treatment of acute pain. The null hypothesis was that no difference between celecoxib and ibuprofen exists.\n                    <jats:bold>Methods:<\/jats:bold>\n                    The study was a prospective, randomized, double\u2010blind, controlled clinical trial. After consent, patients rated their pain on a 100\u2010mm visual analog scale (VAS) and categorical intensity pain scale. Patients were then randomized to receive 200\u2010mg or 400\u2010mg celecoxib or 600\u2010mg ibuprofen (all orally). Patients were contacted 5 hours after receiving study medication when a second VAS score was recorded, along with categorical pain intensity, pain relief score, side effects, and number of rescue medications taken. The main outcome measures were change in visual analog pain and categorical pain intensity scores, and pain relief scores, at five hours.\n                    <jats:bold>Results:<\/jats:bold>\n                    One hundred ten patients were evaluated and 105 were enrolled. Thirty\u2010four received celecoxib 200 mg, 32 received celecoxib 400 mg, and 39 received ibuprofen 600 mg. Ninety\u2010one were available for the five\u2010hour VAS and 88 for the five\u2010hour categorical pain intensity and pain relief analysis: The two patients who were unable to read a VAS were excluded, and two enrolled patients withdrew prior to medication. One patient was excluded because his injury was a fracture, and therefore did not meet the inclusion criteria. There was no statistical difference among the treatment groups in age, time from injury to medication, initial VAS score, percent lost to follow\u2010up, or treatment with adjunctive therapy. There was no statistical difference in change of VAS among the groups at five hours: ibuprofen 600 mg (\u201023.8 mm [95% CI = \u201031.56 mm to \u201016.1 mm] [n = 32]), celecoxib 200 mg (\u201016.1 mm [95% CI = \u201024.3 mm to \u20107.98 mm] [n = 31]), and celecoxib 400 mg (\u201012.4 mm [95% CI = \u201023.1 mm to \u20101.8 mm] [n = 30]) (p = 0.16). There was no significant difference between the groups, at five hours, in change of categorical pain intensity (p = 0.11) or pain relief scores (p = 0.059), though the pain relief scale approached significance favoring ibuprofen.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    No significant difference exists among emergency department (ED) patients treated for acute pain, at five hours, with celecoxib 200 mg, celecoxib 400 mg, or ibuprofen 600 mg, though the power of the study to detect a change was low, 36%. However, the magnitude of pain relief for celecoxib, coupled with the cost of the medication, questions its use in the immediate ED setting.\n                  <\/jats:p>","DOI":"10.1197\/aemj.10.1.22","type":"journal-article","created":{"date-parts":[[2003,1,2]],"date-time":"2003-01-02T14:28:53Z","timestamp":1041517733000},"page":"22-30","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Randomized, Clinical Trial Comparing Oral Celecoxib 200 mg, Celecoxib 400 mg, and Ibuprofen 600 mg for Acute Pain"],"prefix":"10.1111","volume":"10","author":[{"given":"David F.","family":"Salo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lavery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Varma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Kenwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)12154-2"},{"issue":"49","key":"e_1_2_1_3_1","first-page":"20","article-title":"Pain management in osteoarthritis: the role of COX\u20102 inhibitors","volume":"24","author":"Lane NE","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(96)70238-X"},{"key":"e_1_2_1_6_1","unstructured":"CDC National Center for Disease Statistics. Available at:http:\/\/www.cdc.govnchsproductspubspubdhustables200000hus084.pdf. Accessed Feb 2002."},{"issue":"5","key":"e_1_2_1_7_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9343(99)00116-3","article-title":"Cyclooxygnease\u20102 specificity and its clinical implications","volume":"106","author":"Lefkowith JB","year":"1999","journal-title":"Am J Med"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.22.13313"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.1.64"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(99)80045-9"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161060-00019"},{"key":"e_1_2_1_12_1","unstructured":"PocratesRx Clinical Drug Database. Available at:http:\/\/www.epocrates.com. Accessed Mar 2002."},{"key":"e_1_2_1_13_1","first-page":"S22","article-title":"Comparison of efficacy between celecoxib and naproxen or ibuprofen in the treatment of ankle sprain [abstract 71]","volume":"38","author":"Petrella R","year":"2001","journal-title":"Ann Emerg Med"},{"key":"e_1_2_1_14_1","first-page":"S22","article-title":"Efficacy of celecoxib compared with ibuprofen in the treatment of ankle sprain [abstract 72]","volume":"38","author":"Ekman E","year":"2001","journal-title":"Ann Emerg Med"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.41.1.815"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2.1.139"}],"container-title":["Academic Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1197%2Faemj.10.1.22","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1197\/aemj.10.1.22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T11:14:10Z","timestamp":1700219650000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1197\/aemj.10.1.22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":15,"aliases":["10.1111\/j.1553-2712.2003.tb01972.x"],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1197\/aemj.10.1.22"],"URL":"https:\/\/doi.org\/10.1197\/aemj.10.1.22","archive":["Portico"],"relation":{},"ISSN":["1069-6563","1553-2712"],"issn-type":[{"value":"1069-6563","type":"print"},{"value":"1553-2712","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]},"assertion":[{"value":"2008-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}